JP2977894B2 - 自己免疫疾患用剤 - Google Patents

自己免疫疾患用剤

Info

Publication number
JP2977894B2
JP2977894B2 JP2507957A JP50795790A JP2977894B2 JP 2977894 B2 JP2977894 B2 JP 2977894B2 JP 2507957 A JP2507957 A JP 2507957A JP 50795790 A JP50795790 A JP 50795790A JP 2977894 B2 JP2977894 B2 JP 2977894B2
Authority
JP
Japan
Prior art keywords
cells
animals
och
arthritis
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2507957A
Other languages
English (en)
Japanese (ja)
Other versions
JPH04507096A (ja
Inventor
モードレル，マヌエル
ムンダー，ゲルハルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU
Original Assignee
MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU filed Critical MATSUKUSU PURANKU G TSUA FUERUDERUNKU DERU UITSUSENSHAFUTEN EE FUAU
Publication of JPH04507096A publication Critical patent/JPH04507096A/ja
Application granted granted Critical
Publication of JP2977894B2 publication Critical patent/JP2977894B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2507957A 1989-06-02 1990-05-31 自己免疫疾患用剤 Expired - Fee Related JP2977894B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3918082.4 1989-06-02
DE3918082A DE3918082A1 (de) 1989-06-02 1989-06-02 Mittel gegen autoimmunerkrankungen

Publications (2)

Publication Number Publication Date
JPH04507096A JPH04507096A (ja) 1992-12-10
JP2977894B2 true JP2977894B2 (ja) 1999-11-15

Family

ID=6381972

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2507957A Expired - Fee Related JP2977894B2 (ja) 1989-06-02 1990-05-31 自己免疫疾患用剤

Country Status (14)

Country Link
US (1) US5266564A (enExample)
EP (1) EP0474712B1 (enExample)
JP (1) JP2977894B2 (enExample)
AT (1) ATE94757T1 (enExample)
AU (1) AU5670690A (enExample)
CA (1) CA2056421C (enExample)
CS (1) CS276439B6 (enExample)
DE (2) DE3918082A1 (enExample)
DK (1) DK0474712T3 (enExample)
ES (1) ES2060173T3 (enExample)
GR (1) GR1001195B (enExample)
IE (1) IE64039B1 (enExample)
WO (1) WO1990014829A1 (enExample)
ZA (1) ZA904196B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3941009A1 (de) * 1989-12-12 1991-06-13 Medmark Pharma Gmbh Eliminierung von aktivierten lymphozyten
ATE239041T1 (de) * 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
US6583127B1 (en) 1998-12-21 2003-06-24 Inkeysa. Sa Use of etherlysophospholipids as antiinflammatory agents
SE9902155L (sv) * 1999-06-09 2000-12-10 Bjoern Rydevik Serum antibodies
JP2002228764A (ja) * 2001-02-02 2002-08-14 Fuji Photo Film Co Ltd 透光性シート体検出装置
WO2008055997A1 (en) * 2006-11-10 2008-05-15 Alphaptose Gmbh Use of tri-substituted glycerol compounds for the treatment of radiation injuries
JP5773569B2 (ja) 2006-11-10 2015-09-02 アルファプトーゼ ゲーエムベーハーＡｌｐｈａｐｔｏｓｅ Ｇｎｂｈ 受容体リガンド模倣体を検出する方法
DK2091520T3 (da) * 2006-11-10 2012-06-18 Alphaptose Gmbh Oral doseringsform omfattende trisubstituerede glycerol-forbindelser
EP2120873B1 (en) * 2006-12-20 2012-06-27 Alphaptose Gmbh Topical dosage form comprising tri-substituted glycerol compounds
PL2144618T5 (pl) * 2007-03-28 2025-07-21 Aker Biomarine Human Ingredients As Bio-skuteczne kompozycje oleju z kryla
US8697138B2 (en) 2007-03-28 2014-04-15 Aker Biomarine As Methods of using krill oil to treat risk factors for cardiovascular, metabolic, and inflammatory disorders
US20100226977A1 (en) * 2007-08-29 2010-09-09 Aker Biomarine Asa Low viscosity phospholipid compositions
US20090061067A1 (en) * 2007-08-29 2009-03-05 Aker Biomarine Asa Method for making krill meal
US8372812B2 (en) * 2009-02-26 2013-02-12 Aker Biomarine Asa Phospholipid and protein tablets
WO2013156630A1 (en) 2012-04-20 2013-10-24 Alphaptose Gmbh S-enantiomer of a tri-substituted glycerol compound
AU2014203179C1 (en) 2013-06-14 2017-05-04 Aker Biomarine Antarctic As Lipid extraction processes
GB201400431D0 (en) 2014-01-10 2014-02-26 Aker Biomarine As Phospholipid compositions and their preparation
EP3256553A2 (en) 2015-02-11 2017-12-20 Aker Biomarine Antarctic AS Lipid compositions
WO2016128830A1 (en) 2015-02-11 2016-08-18 Aker Biomarine Antarctic As Lipid extraction processes

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2009343C3 (de) * 1970-02-27 1980-10-23 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Lysolecithinen als immunologische Adjuvantien
DE2009342C3 (de) * 1970-02-27 1980-12-18 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V., 3400 Goettingen Verwendung von Glycerin-alkyläther-(l)-phosphorsäure-(3)-monocholinestern
DE2619686C2 (de) * 1976-05-04 1986-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen Verwendung eines Lysolecithins zur Tumorbehandlung
CH670763A5 (enExample) * 1985-08-02 1989-07-14 Seuref Ag
DE3530767A1 (de) * 1985-08-28 1987-03-12 Max Planck Gesellschaft Mittel gegen multiple sklerose

Also Published As

Publication number Publication date
ZA904196B (en) 1991-03-27
CA2056421A1 (en) 1990-12-03
IE64039B1 (en) 1995-06-28
GR1001195B (el) 1993-06-07
EP0474712A1 (de) 1992-03-18
DE3918082A1 (de) 1991-01-24
US5266564A (en) 1993-11-30
ATE94757T1 (de) 1993-10-15
AU5670690A (en) 1991-01-07
DE59002863D1 (de) 1993-10-28
ES2060173T3 (es) 1994-11-16
IE901987L (en) 1990-12-02
DK0474712T3 (da) 1993-11-29
CS276439B6 (en) 1992-05-13
GR900100406A (en) 1991-11-15
CS268990A3 (en) 1992-01-15
JPH04507096A (ja) 1992-12-10
EP0474712B1 (de) 1993-09-22
WO1990014829A1 (de) 1990-12-13
CA2056421C (en) 2000-10-10
DE3918082C2 (enExample) 1992-02-06

Similar Documents

Publication Publication Date Title
US5266564A (en) Method for treating certain autoimmune diseases
JP2512796B2 (ja) 自己抗原の経口投与による自己免疫疾患の治療法
KR0140841B1 (ko) 자기항원의 경구 투여에 의한 자기면역 질병의 치료
KR100294060B1 (ko) 면역억제제로서히알루론산을이용하는방법
JPH0667827B2 (ja) メイラード反応阻害剤
KR0161235B1 (ko) 포유류에서의 이인자형이식 거부를 억제하는 방법 및 조성물
KR19980701585A (ko) 골용해와 전이를 개선하기 위한 조성물(composition to ameliorate osteolysis and metastasis)
JPH03503887A (ja) 自己免疫疾患に対する抗ｔ細胞イムノトキシンの治療的使用
EP0251134B1 (en) Compositions for preventing graft rejection
CA2860678A1 (en) Partial mhc constructs and methods of use
KR100371000B1 (ko) 류머티즘치료제
JP2002513765A (ja) 免疫応答の調節における無視された標的組織抗原の使用
US5206223A (en) Method for inhibiting heparanase activity
JP2016155814A (ja) 免疫応答を低減して免疫状態を治療する方法
AU2003250892A1 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
US4778788A (en) Agent against multiple sclerosis
Austen The heterogeneity of mast cell populations and products
JP2010235607A (ja) 自己免疫疾患の診断薬と治療薬となるペプチド類
JPH10212230A (ja) Ｈｓｐ６０ファミリーに属するタンパク質のジヒドロキシナフトキノン化合物含有合成抑制剤
FI80711C (fi) Foerfarande foer framstaellning av en terapeutiskt anvaendbar termiskt denaturerad, till en glykosidbindning ansluten antigen (gra), som haerroer sig fraon cancerceller.
DE69224795T2 (de) 4Verfahren und Zusammensetzungen zur Vorbeugung, Diagnose und Behandlung seröser Entzündungen und damit verbundener Störungen
US20030007964A1 (en) Method for treating rheumatoid arthritis with composition containing histone
EP1140118A1 (en) Cyclic adenosine diphosphate ribose analogues for modulating t cell activity
EP1807091A1 (en) Novel use of ligands specific to fex-2 polypeptide
US20060034837A1 (en) Method and agents for the prevention, inhibition and therapy of cancers

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080910

Year of fee payment: 9

LAPS Cancellation because of no payment of annual fees